Microbiotica United Kingdom

Microbiotica was launched in December 2016 with the aim of creating a global leader to exploit the leading microbiome science built at the Wellcome Trust Sanger Institute. The company retains a close association with the Sanger Institute and its founders and is based at the Wellcome Genome Campus, Cambridge UK.

Dr Nigel Crockett
Head Business Development 

Micromatrices United Kingdom

MicroMatrices offers services and technologies to facilitate smarter compound selection and de-risk drug development by resolving targets that might not be detected with currently available platforms. We specialise in multiparameter analytics for in vitro 3D cell cultures, known to be more predictive and human-relevant than 2D cultures.

Our  SpheroMatrices® (patent pending) enhanced analytics for 3D cell cultures, a spheroid  tissue microarray technology,  can be used to assess complex responses earlier in development to weed out compounds that might cause issues further down the pipeline.

We use a suite of pathology-guided  molecular toxicological  approaches in combination with innovative visualisation/localisation technologies which can add  significantly enhanced resolving power to  standard in vitro assays.

We can also adopt these approaches to FFPE tissues from in vivo  studies, a cost and time effective method which unlocks the potential of these tissues for investigating mechanisms of toxicity and improving predictive capability.

Since 2011, MicroMatrices innovative and collaborative investigations have produced valuable information, saving time and money,  for our clients in the areas of Early Discovery, Preclinical Safety & Efficacy, Toxicology, Biomarker Discovery and Investigative Toxicology.

We look forward to meeting Pharma companies and CROs  to discuss areas of mutual interest in Berlin.

Dr Simon Plummer
Managing Director 

Mironid United Kingdom

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.

Dr Neil Wilkie
COO 
Dr Alan Lamont
CBO 

NIHR Clinical Research Network United Kingdom

Exhibiting at booth 82

Funded by UK government, the National Institute for Health Research (NIHR) Clinical Research Network (CRN) is the clinical research delivery arm of the National Health Service (NHS) in England. We support rapid study set-up and patient recruitment into all phases of clinical research studies, across all therapeutic areas. 

We’ve recruited over three million patients into clinical studies in the NHS over the last five years and created a thriving environment for conducting large scale commercial contract clinical research, so that life sciences companies can allocate clinical studies to the UK with confidence. At the core of this success is our Study Support Service - a package of free-of-charge services covering the life cycle of a clinical study including feasibility, set-up, costings and contracts, and performance monitoring to enable recruitment to agreed time and target. 

Talk to us to find out more about what we can do for you.

 

Phone: +00 44 (0)113 34 34 555

Email: supportmystudy@nihr.ac.uk

Web: http://www.nihr.ac.uk/industry

Organisation type
Mr Theo Christie
Business Development Manager 
Mrs Natalie Wilson
Business Development Analyst 

Northern Health Science Alliance United Kingdom

Exhibiting at booth 83/84

 The Northern Health Science Alliance provides one access point to the health science ecosystem in the North of England creating a simple way for organisations to access the resources and expertise available in eight major cities.

www.theNHSA.co.uk @The_NHSA

      

Organisation type
Ms Suzanne Ali-Hassan
Business Development Manager 

Oncimmune United Kingdom

Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and can be applied to a wide range of solid tumour types. 

We are also applying autoantibody profiling to patient stratification in immuno-oncology, where we measure how the immune system is recognising the presence of tumour antigens.

Dr Michael Fisher
Dr Michael Fisher
Commercial Director 

OxStem United Kingdom

OxStem is a drug discovery company, spun-out from the University of Oxford, with the unique vision of developing in-situ cell programming therapies to treat what are typically (but certainly not exclusively) age-related conditions, such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world), Diabetes and Oncology. 

The idea is straightforward - to use the Stem Cell and Medicinal Chemistry expertise within Chemistry and its associated partners at Oxford to identify new classes of drugs that can re-program or stimulate existing endogenous cells - awakening previously defunct or dormant cellular processes.

Dr Michael Stein
CEO 

PHASTAR United Kingdom

Exhibiting at booth 82

PHASTAR work with pharmaceutical and biotechnology companies to provide statistical consulting and to collect, summarise, analyse and report the data used in clinical trials.  Our top priority is the quality of our work, ensuring we give you the best statistical advice, and analyse your clinical data optimally, getting it right first time. There are lots of different ways to analyse a set of data. We can advise on how to get the most out of your data. Statistics is an art!

We can work with our own internal systems and processes or seamlessly incorporate with your teams. We can manage and deliver whole clinical trial programs, or give you advice on a trial you are planning.

Organisation type
Mr Kevin Kane
CEO 

Scottish Development International United Kingdom

Scottish Development International (SDI) is the international arm of Scotland’s enterprise agencies with a proven track record of helping companies succeed in business in Scotland.

We can offer significant financial incentives and other assistance to help establish and grow your business in Scotland and worldwide. With a network of 31 overseas offices in 19 countries across the globe, our role is to assist Scottish companies to access new international markets, attract new investment projects, and support existing inward investments in Scotland.  

SDI can offer assistance  in the following areas: 

  • Identify and secure the skills and talent you need
  • Train and develop staff
  • Finance capital investment, innovation and research & development
  • Improve manufacturing and energy efficiency
  • Develop leadership skills
Organisation type
Mrs Emily Lekkas
International Senior Executive 
Mrs Katharina Kraehahn
Senior Business Development Executive 

Seda Pharmaceutical Development Services Ltd United Kingdom

Exhibiting at booth 83/84

The integrated Pharmaceutical Development and Clinical Pharmacology Service that maximises value build.

By choosing Seda you can rest assured you are in safe hands. Our team have delivered high quality products, processes and regulatory submissions leading to the approval and launch of several successful medicines. We have practiced across therapeutic areas and have extensive experience in the development of Oncology drugs, including those with ‘breakthrough’ status.

Seda are pioneers of novel approaches to accelerate projects that can save you money and create better value. Our team of experts have deep scientific experience across a broad range of disciplines and stages of development, from discovery to launch.

Strategy > Design > Data > Interpretation > Execution

 

  • Consultancy
  • Physicochemical characterisation and preformulation studies
  • Solid form selection including polymorphs, salts and co-crystals
  • Preclinical safety study formulation development for challenging molecules
  • First-time-in-clinic and later phase / commercial formulation development
  • Enabling formulations and specialist drug delivery technology selection
  • Preclinical DMPK
  • Absorption and PK-PD Modeling
  • GMP Audits
  • Quality Systems (GMP supply aspects) for Clinical Study Sponsors
  • Clinical pharmacokinetics and Biopharmaceutics
  • Due diligence, competitor analysis and technology opportunity assessments
  • Scientific leadership: academic - industry collaborations; training and mentoring; scientific advisory boards 

Routes of administration and technology areas we cover:

Oral

  • Immediate release
  • Modified release
  • Oral poorly solubles

 Standard Injectables 

 Complex Injectables

  • Poorly soluble IV
  • Depot
  • Targeted 
Organisation type
Dr Paul Dickinson
Director 
Dr Marcel de Matas
Director